Risk factors and outcome of COVID-19 in patients with hematological malignanciesJosé Luís Piñana, Anna Sureda, Rodrigo Martino et al.|Experimental Hematology and Oncology|2020Cited by 159
S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIBJuan Miguel Bergua Burgués, Pau Montesinos, Mercedes Colorado et al.|HemaSphere|2023Cited by 6
A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema TrialJuan Miguel Bergua Burgués, Pau Montesinos, Raquel Tarazona et al.|Blood|2023Cited by 1